Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Claxton

Showing results (51-60 of 118) with videos related to

Pageof 12
Sort By:
BMJ Open|September 11, 2023
Is extending eligibility for adult social care better than investing more in existing users in England? A cross-sectional evidence for multiple financial yearsFrancesco Longo, Karl Claxton, James Lomas, et al.
Applied Health Economics and Health Policy|August 4, 2005
Using value of information analysis to inform publicly funded research prioritiesLaura Ginnelly, Karl Claxton, Mark J Sculpher, et al.
Health Economics|October 5, 2024
Unpacking the care-related quality of life effect of England's publicly funded adult social care. A panel data analysisAndrea Salas-Ortiz, Francesco Longo, Karl Claxton, et al.
Health Economics|February 24, 2006
Whither trial-based economic evaluation for health care decision making?Mark J Sculpher, Karl Claxton, Mike Drummond, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|February 18, 2020
Estimating Social Variation in the Health Effects of Changes in Health Care ExpenditureJames Love-Koh, Richard Cookson, Karl Claxton, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|September 21, 2020
Valuing health outcomes: developing better defaults based on health opportunity costsJessica Ochalek, Karl Claxton, James Lomas, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|February 12, 2008
Identifying research priorities: the value of information associated with repeat screening for age-related macular degenerationLaura Bojke, Karl Claxton, Mark J Sculpher, et al.
Health Policy (Amsterdam, Netherlands)|March 16, 2024
Apples and orangesKarl Claxton, James Lomas, Francesco Longo, et al.
Pharmacoeconomics|May 21, 2018
Discounting in Economic EvaluationsArthur E Attema, Werner B F Brouwer, Karl Claxton
Health Economics|December 10, 2014
Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients?Karl Claxton, Mark Sculpher, Stephen Palmer, et al.
Pageof 12

Showing results (51-60 of 118) with videos related to

Sort By:
Pageof 12
BMJ Open|September 11, 2023
Is extending eligibility for adult social care better than investing more in existing users in England? A cross-sectional evidence for multiple financial yearsFrancesco Longo, Karl Claxton, James Lomas, et al.
Applied Health Economics and Health Policy|August 4, 2005
Using value of information analysis to inform publicly funded research prioritiesLaura Ginnelly, Karl Claxton, Mark J Sculpher, et al.
Health Economics|October 5, 2024
Unpacking the care-related quality of life effect of England's publicly funded adult social care. A panel data analysisAndrea Salas-Ortiz, Francesco Longo, Karl Claxton, et al.
Health Economics|February 24, 2006
Whither trial-based economic evaluation for health care decision making?Mark J Sculpher, Karl Claxton, Mike Drummond, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|February 18, 2020
Estimating Social Variation in the Health Effects of Changes in Health Care ExpenditureJames Love-Koh, Richard Cookson, Karl Claxton, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|September 21, 2020
Valuing health outcomes: developing better defaults based on health opportunity costsJessica Ochalek, Karl Claxton, James Lomas, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|February 12, 2008
Identifying research priorities: the value of information associated with repeat screening for age-related macular degenerationLaura Bojke, Karl Claxton, Mark J Sculpher, et al.
Health Policy (Amsterdam, Netherlands)|March 16, 2024
Apples and orangesKarl Claxton, James Lomas, Francesco Longo, et al.
Pharmacoeconomics|May 21, 2018
Discounting in Economic EvaluationsArthur E Attema, Werner B F Brouwer, Karl Claxton
Health Economics|December 10, 2014
Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients?Karl Claxton, Mark Sculpher, Stephen Palmer, et al.
Pageof 12